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Abstract
Dendritic cells (DCs) represent a population of innate immune cells that are
highly efficient at promoting immune responses. DCs are capable of presenting antigens
to both CD4 and CD8 T cells. DC presentation and interaction with T cells can result in
either immune stimulation or tolerance. This study intends to phenotype a rare subset of
DCs found in the human blood and is distinguishable by the expression of various surface
markers including: lineage markers (Lin), HLADR, CD1c, and CD141 or BDCA-3.
Stimulating BDCA-3 DCs with Poly I:C, a toll-like receptor (TLR) 3 agonist, resulted in
the up-regulation of various canonical activation markers such as CD40, CD80, and
CD86 as well as immunoglobulin-like transcript (ILT) 3 and 4 as measured by flow
cytometry. ILTs are novel surface molecules with implicated inhibitory functions and are
selectively expressed by APCs, such as DCs. The surface induction of ILT3 and ILT4
occurred in both time- and dose-dependent manner. The up-regulation of ILT3 and ILT4
within the BDCA-3 subset of DCs resulted in the unexpected formation of various
subsets of BDCA-3 DCs expressing: ILT3- ILT4-, ILT3- ILT4+, ILT3+ ILT4-, and ILT3+
ILT4+. Due to limited numbers of cells, we focused our efforts to determine the
biological differences between ILT3---ILT4- and -ILT4+ BDCA-3 DCs after Poly I:C
stimulation. This study will show that these two populations of BDCA-3 DCs differ in
their cytokine secretion profile, genomic signature, and their ability to prime allogenic
naïve T cells.
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Introduction
The immune system consists of an intricate network of cells that are capable of
detecting both foreign and selfantigens. The process of eliminating foreign antigens and
the ability to tolerate self-antigens occur within both innate and adaptive immunity.
Innate immunity is shared by all multi-cellular organisms and is considered to be a nonspecific first line of defense. Components of innate immunity include epithelial barriers,
phagocytes, dendritic cells (DCs), natural killer (NK) cells, and the complement system.
Detection of microbes through innate immunity is achieved by the use of pattern
recognition receptors (PRRs) that detect pathogen-associated molecular patterns
(PAMPs). PRRs detect foreign substances, but may also detect self-components as
danger signals in the presence of infection, inflammation, or other cellular stress
(Mogensen, 2009). Adaptive immunity evolved in vertebrates as a means to detect and
form a memory response against microbes that have evaded the innate response. There
are two types of adaptive immunity, humoral and cell-mediated. Each type of adaptive
immunity has the unique ability to achieve a memory of the response, thus subsequent reinfections can be quickly eliminated. Cross-talk occurs between both branches of the
immune system to orchestrate both the elimination of microbes as well as the induction of
a memory response. This cross-talk is mediated through cells known as antigen
presenting cells (APCs), which include B cells, monocytes, macrophages, and DCs. DCs
are considered the primary APCs for the activation of naïve T cells. The discovery of
human splenic DCs in 1973 by Ralph Steinman and Zanvil Cohn has led to an ever
expanding identification of novel DC subsets (Steinman and Cohn, 1973). APCs have
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the unique ability to process both intracellular and internalized proteins and display
peptides on major histocompatibility complex (MHC) molecules. MHC molecules can
be divided into two classes, MHC I and MHC II molecules. All nucleated cells express
the MHC class I molecules whereas MHC class II molecules are only expressed by APCs
(Ting and Trowsdale, 2002, Hewitt, 2003). T cells are capable of detecting peptides
displayed on both MHC molecules through the T cell receptor (TCR). Cytotoxic CD8+ T
cells have a TCR that recognizes peptides presented on MHC class I molecules while
CD4+ TCR recognizes peptides bound to MHC class II molecules (Ting and Trowsdale,
2002, Hewitt, 2003). The extraordinary genetic diversity that contributes to the specificity
of MHC molecules coupled with the numerous genetic rearrangements involved in the
production of diverse TCR repertoires has enabled the immune system to keep up with
the ever so changing microbial, viral and tumor environment (Robins et al., 2009).
DCs have been identified to populate various organs including the skin, lung,
intestinal tract, liver, kidney, and blood. They can be sub-divided by their cellular
precursors, migratory capacity, and whether or not they exhibit a DC phenotype in a
steady-state condition. In the broadest sense, one can classify DCs as conventional or
non-conventional. Conventional DCs exhibit classical DC function and are derived from
a common DC progenitor (CDP) and can be further divided into migratory and lymphoid
DCs. On the other hand, non-conventional DCs, including plasmacytoid DCs (pDCs),
are derived from a pre-DC population along with monocyte-derived DC subsets and are
found in various peripheral organs (Kushwah and Hu, 2011). The identification of the
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various DC populations is facilitated by the surface markers expressed on the cell
membrane called clusters of differentiation (CD).
This study focuses on human blood DC subsets. Blood DCs are rare leukocytes
making up approximately 0.16-1.63% of total peripheral blood leukocytes (Haller
Hasskamp et al., 2005). Human blood DCs consist of three distinct subsets characterized
by their differential expression of three surface markers, termed blood dendritic cell
antigens (BDCA), namely BDCA-1 (CD1c), BDCA-2 (CD303), and BDCA-3 (CD141).
Each marker selectively identifies cDCs, pDCs, and CD141+ cDCs respectively. cDCs
are primarily responsible for bacterial clearance and cross-presentation to CD8 T cells
(Kushwah and Hu, 2011). pDCs are involved in viral elimination and upon stimulation
produce large amounts of type I interferons (Swiecki and Colonna, 2010).
Each subset of blood DCs expresses different levels of environment sensing
receptors to detect PAMPs called Toll-like receptors (TLRs). Currently, through genomic
analysis, ten human TLRs have been identified. TLRs 1, 2, 4-6 and 11 physically reside
on the surface of the cell membrane, while TLRs 3, 7-9 are localized to the endosomal
compartments. All TLRs, except for TLR3, signal through the adaptor protein MyD88 or
through a MyD88 independent pathway, which results in NF-κB activation. TLR3 and
TLR4 signal through the TRIF-dependent pathway. The activation of NF-κB ultimately
influences the genes encoding various cytokines. TLR signaling through different DC
subsets results in a unique cytokine secretion profile (Kawai and Akira, 2010). TLR1 has
been shown to be involved in detecting microbial lipoproteins potentially by associating
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with TLR2 (Takeuchi et al., 2002). The natural ligand for TLR1 however still remains
elusive. TLR2 has been shown to recognize a wide variety of bacterial cell wall
components through heterodimerization with either TLR1 or TLR6 (Kadowaki et al.,
2001). TLR3 recognizes double-stranded RNA typically generated by actively replicating
viruses and upon activation results in the production of type I Interferons (Alexopoulou et
al., 2001). The natural ligand for TLR4 is lipopolysaccharide (LPS) from gram-negative
bacteria which upon activation leads to the induction of pro-inflammatory cytokines (Lu
et al., 2008). TLR5 has been shown to specifically interact with flagellin from both gramnegative and gram-positive bacteria. Activation of TLR5 results in the production of
TNF-α (Hayashi et al., 2001). TLR6 activation typically occurs when the receptor
heterodimerizes with TLR2. Lipopeptides have been shown to heterodimerize TLR2 with
TLR6 signaling through the MyD88 adaptor protein and activation of NF-κB (Takeuchi
et al., 1999, Farhat et al., 2008). TLR7 activation was initially discovered through
interactions with small anti-viral imidazoquinoline-derived compounds such as
imiquimod and resiquimod (R-848). Further studies revealed that the natural ligand for
TLR7 is single strand viral RNA. More recently, studies have shown that bacterial RNA
can also be detected by TLR7 (Mancuso et al., 2009). TLR7 activation results in the
secretion of type one interferons, IFN-α, by pDCs (Hemmi et al., 2002, Diebold et al.,
2004). TLR8 is both genetically and functionally similar to TLR7 as recent studies have
shown that TLR7 can detect bacterial RNA. Similar studies have shown that TLR8 can
detect bacterial RNA released within phagosomal vacuoles. Activation of TLR8 results in
the release of type one interferons, specifically IFN-β (Cervantes et al., 2012).
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Interestingly, TLR8 is involved in TLR to TLR cross-talk. Studies have shown that
human TLR8 activation inhibits the activation of TLR7 and 9 (Wang et al., 2006). TLR9
has been shown to selectively detect unmethylated CG dinucleotides present in microbial
DNA. Un-methylated CG dinucleotides (CpG) are not common in the vertebrate genome
and have been shown to be immunostimulatory through TLR9 recognition (Bauer et al.,
2001, Rutz et al., 2004).
TLRs are mainly expressed on APCs including monocytes, dendritic cells, and B
cells. In the blood, human BDCA-1 and BDCA-3 cDCs selectively express TLRs 2-6, 9
and 3, respectively, and produce large amounts of IL-12 during antibacterial and antiviral
responses (Jongbloed et al., 2010, Gupta et al., 2013). In contrast, human BDCA-2 pDCs
express TLR7 and TLR9 and have the ability to produce a large amount of type 1
interferons (IFNs) in antiviral immune responses (Colonna et al., 2004). There are
species-specific differences in the expression of TLRs across human and murine
leukocytes. Mouse pDCs express TLRs 3,4,7-9 while human pDCs mainly express TLRs
7 and 9. Mouse myeloid DCs express TLR9 while human myeloid DCs do not (Ketloy et
al., 2008). Due to the rarity of primary blood DCs, many studies rely on monocyte
derived dendritic cells (moDCs), which can be generated in large quantities in vitro by
exposing monocytes to various growth factors such as IL-4 and GM-CSF (Sallusto and
Lanzavecchia, 1994). Although useful, moDCs are phenotypically and functionally
distinct from freshly isolated primary DCs. MoDCs express TLR9 and CD209 while
blood CD11c+ DCs do not. Blood DCs generate greater T lymphocyte proliferative
responses as well as Th1 effectors compared to moDCs (Osugi et al., 2002, Hoene et al.,
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2006). Therefore, care must be taken interpreting data derived from moDCs and the
translatability of those findings to primary blood DCs.
DC TLR engagement by their respective ligands leads to the up-regulation of
various canonical activation markers, including but not limited to CD40, CD80, and
CD86. CD40 is a member of the TNF receptor family. Activation of CD40 by its receptor
CD40 ligand (CD40L) results in DC cytokine secretion, co-stimulatory molecule
migration to the cell surface, and enhanced antigen presentation (Elgueta et al., 2009).
CD80 and CD86 provide co-stimulatory signals to T cells to enhance their proliferation,
cytokine secretion, and maturation status (Lanier et al., 1995). Following DC activation, a
naïve T cell that encounters a DC through TCR-MHCI/II interaction can be primed
toward a particular phenotype. The outcome of such a priming event is dependent on the
maturation status and the type of DC a naïve T cell encounters in the lymphoid tissue.
CD4 T cell priming by DCs can yield various T helper (Th) phenotypes that exhibit a
unique cytokine secretion profile. Th1 T cells predominately secrete IFN-ɣ and are
typically involved in autoimmune disease pathogenesis and host defense against
intracellular pathogens. Th2 T cells secrete IL-4 and IL-5 and are associated with atopic
diseases and are involved in the expulsion of extracellular parasite elimination. Th17
cells produce IL-21 and IL-17 and are involved in extracellular bacterial and fungi
elimination, as well as certain autoimmune disease. Finally T regulatory cells secrete
TGF-β and IL-10 and are involved in immune tolerance (Zhu and Paul, 2008).
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Along with pro-inflammatory signals, DCs are also capable of promoting
tolerogenic responses. cDCs and pDCs under certain environmental conditions have been
reported to prime naïve T cells into T regulatory cells (Tregs) (Kushwah and Hu, 2011).
Recently, a subset of DCs has been shown to express the immunoglobulin-like transcript
(ILT) receptors. ILTs, such as ILT3 and ILT4, have been demonstrated to be expressed
on monocytes and DCs. The cytoplasmic region of ILT molecules contains a putative
immuno-receptor tyrosine-based inhibitory motif, suggesting an inhibitory function of
ILT receptors. Consistent with the proposed inhibitory function, ILT3 has been shown to
induce immunosuppression, including T cell anergy, regulatory T cell (Treg) induction,
and reduced allo-stimulatory capacity (Chang et al., 2002, Manavalan et al., 2003). ILT4
expression has also been implicated in the role of DCs to prime Tregs, however its
prevalence within the literature is quite limited (Manavalan et al., 2003).
The current study focuses on the phenotypic and functional characterization of the
BDCA-3 subset of blood DCs. Each subset of blood DCs expresses different levels of
TLRs. Transcriptional profiling of various TLR receptors within a particular DC subset
and responsiveness to multiple TLR agonists suggests two hypotheses (A) on per cell
basis BDCA-3 DCs express multiple TLRs or (B) there may exist various BDCA-3 DC
subsets each with a unique TLR expression. The recent discovery of a human
XCR1+CD141+ DC subset expressing TLR3 within the conventional DC population
supports the latter hypothesis (Bachem et al., 2010). This discovery raises the possibility
that multiple yet-to-be-identified populations of BDCA-3 DCs may exist. We intend to
show that stimulating primary human blood BDCA-3 DCs with Poly I:C, a TLR3
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agonist, results in the formation of various populations identifiable by inhibitory
receptors ILT3 and ILT4. These populations will be phenotypically assessed for genomic
differences as well as their ability to secrete cytokines and prime T cells. Finally, the
current study contributes to the overall understanding of various human DC subsets.
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Materials and Methods
i.

Isolation and Culture of Human Cells.

Total blood leukapheresis from healthy anonymous donors was purchased from
Research Blood Components LLC (Brighton, MA). Total peripheral blood mononuclear
cells (PBMCs) were isolated after lysis of red blood cells. Cells were first washed in PBS
containing 0.5% human serum albumin. Next, red blood cells were lysed in ACK buffer
at 37oC for 10 minutes. Cells were then spun down at 300g for 5 minutes and
resuspended in StemCell wash buffer. Total DCs were first enriched using the Human
Myeloid DC Enrichment Kit (StemCell Technologies, Vancouver, BC) according to the
manufacturer’s instructions. Enriched DCs were then stained antibodies including lineage
markers (Lin) (BD Bioscience, San Jose, CA), HLADR (BD Bioscience, San Jose, CA),
CD1c (Biolegend, San Diego, CA), CD11c (Miltenyi, San Diego, CA), CD123 (BD
Bioscience, San Jose, CA), and CD141 (Miltenyi, San Diego, CA). Labeled cells were
sorted on a BD FACS ARIA II (BD Biosciences, San Jose, CA). pDCs were sorted based
on the expression of cell surface markers, such as Lin-, CD123+, and HLADR+ . cDCs
were sorted based on cell surface markers such as Lin-, CD123dim, HLADR+, CD1c+,
and CD11c+. BDCA-3 DCs were sorted based on cell surface markers as Lin-,
CD123dim, HLADR+, CD1c-, and CD141+. The purity of collected pDCs, cDCs, and
BDCA-3 DCs was consistently greater than 98% based on post sort analysis. The post
sort purity was determined by acquiring a sorted sample.
ii.

Real time polymerase chain reaction for TLR gene expression (mRNA).
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Total RNA was extracted from a total of 1x106 freshly purified pDCs, cDCs and
BDCA-3 DCs utilizing the RNeasy Plus Mini kit (Qiagen, Valencia, CA). The RNA was
reversely transcribed to cDNA utilizing SuperScript VILO (Invitrogen, Grand Island,
NY). TLRs 1-10 expression was analyzed using Applied Biosystem’s TaqMan Gene
Expression Master Mix and primer/probes. PCR parameters were 50 oC for 2min,
followed by 95 oC for 10min proceeding to 40 cycles of 95 oC for 15 s and 60 oC for 1
min. RPLPO was used as an internal control. Taqman assays were performed on a
BioRad Real-Time PCR System CFX384 (Biorad, Hercules, CA). To determine the
relative expression of each gene, the 2−ΔΔCt approach (ΔCq method) was employed (Livak
and Schmittgen, 2001).
iii.

Gene array experiments.

Purified BDCA-3 DCs were cultured in complete XVIVO-15 (5% human serum
(Sigma) + 1% Pen/Strep) (Invitrogen, Grand Island, NY) media containing 10 µg/mL
Poly I:C at 37oC for 18 hours. Cells were washed and sorted by the expression of ILT3
and ILT4 (R&D Systems, Minneapolis, MN). Total RNA was extracted from ILT3- ILT4, ILT3+ ILT4-, ILT3+ ILT4+ and ILT3- ILT4+ BDCA-3 DCs utilizing the RNeasy Plus
Mini kit (Qiagen, Valencia, CA). RNA was frozen and sent to the Boston University
MicroArray Core for further processing. Briefly, all procedures were performed at
Boston University Microarray Resource Facility as described in GeneChip® Whole
Transcript (WT) Sense Target Labeling Assay Manual (Affymetrix, Santa Clara, CA),
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Nugen Ovation Pico WTA System User Guide, Nugen WT-Ovation ExonModule User
Guide and Nugen Encore Biotin Module User Guide (Nugen, San Carlos, California).
iv.

Microarray Analysis.

Affymetrix GeneChip Human Gene 1.0 ST CEL files were normalized to produce
gene-level expression values using the implementation of the Robust Multiarray Average
(RMA) (Irizarry et al., 2003) in the Affy package (version 1.36.1) (Gautier et al., 2004)
included within in the Bioconductor software suite (version 2.12) (Gentleman et al.,
2004) and an Entrez Gene-specific probeset mapping (version 17.0.0) from the Molecular
and Behavioral Neuroscience Institute (Brainarray) at the University of Michigan (Dai et
al., 2005). Array quality was assessed by computing Relative Log Expression (RLE) and
Normalized Unscaled Standard Error (NUSE) using the affyPLM Bioconductor package
(version 1.34.0). Principal Component Analysis (PCA) was performed using the prcomp
R function with expression values that were unadjusted or were adjusted for donor (by
creating linear models using the lmFit function in the limma package (version 3.14.4),
treating donor as a fixed effect) and had then been normalized across all samples to a
mean of zero and a standard deviation of one. Linear mixed-effects modeling and the
associated analysis of variance were carried out using the anova.lme function in the nlme
package (version 3.1-97). Pairwise differential gene expression was assessed by
performing Student t tests on the coefficients of linear models created using lmFit,
correcting for donor as a fixed effect. Correction for multiple hypothesis testing was
accomplished using the Benjamini-Hochberg false discovery rate (FDR). All microarray
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analyses were performed using the R environment for statistical computing (version
2.15.1).
v.

Identification of Differentially Expressed Genes (DEG).

For comparative analysis, general linear models for microarray data were performed
for probe sets present on the microarray to identify probe sets that were differentially
expressed between the groups, based on moderated t-statistics. Probe sets with a 1.5-fold
change and a P value less than 0.05 were considered biologically significant. Principal
Component Analysis (PCA) was then performed. PCA is a mathematical transform that
collapses the variance between samples across a set of large set of variables (here, all
~20,000 genes on the array) into a much smaller set of variables called Principal
Components (PCs). These "meta-variables" are arranged such that PC1 explains the most
variance in the data, followed by PC2, etc. PCA was performed using all genes across all
samples, either before or after adjusting the expressions for donor (using a simple linear
model), and plots were made of PC1 vs. PC2
vi.

Blood DC TLR activation assay and Poly I:C time course.

After confirming the post sort purity of >98%, 1x105 BDCA-1, BDCA-2, and BDCA3 DCs were plated in 96 well v-bottom plates in complete X-VIVO 15 media (Lonza,
Allendale, NJ). TLR agonists, PAM3CSK4, Poly I:C, LPS, Flagellin, Resiquimod, and
CpG2216 (Invivogen, San Diego, CA) were added at a final concentration of 3µg/mL.
Plates were incubated at 37oC for 18 hours. Cells were then prepared as stated in the
Flow Cytometry section. Plots show the mean of the fold induction from unstimulated
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cells calculated using PRISM v6.0, error bars represent SEM. Time course: 1x106
Purified BDCA-3 DCs were added to a FACS tube in complete X-VIVO media. An
aliquot of cells was removed and stained as stated in the Flow Cytometry section to
acquire an unstimulated sample. Poly I:C was then added at a final concentration of
10µg/mL and cells were incubated at 37oC. An aliquot of cells was removed every hour,
stained, and acquired for the next 8 hours. After 18 hours, a final aliquot was taken and
cells were stained as stated in the Flow Cytometry section.
vii.

BDCA-3 DC activation assay followed by ILT4 sorting.

After confirming the post sort purity of >98%, 1x105 BDCA-3 DCs were plated in 96
well v-bottom plate in complete X-VIVO 15 media (Lonza, Allendale, NJ) (5% human
serum, 2mM L glutamine and 1x penicillin/streptomycin). TLR agonists, Poly I:C and
LPS, (Invivogen, San Diego, CA) were added at a final concentration of 10µg/mL. Plates
were incubated at 37oC for 18hrs. Cells were then harvested and stained with ILT4 (R&D
Systems, Minneapolis, MN). After staining, BDCA-3 DCs were sorted based on the
expression of ILT4 for subsequent analysis.
viii.

Cytokine production assays.

Immediately following sorting, total BDCA-3 DCs were added to a FACS tube
containing Poly I:C at a final concentration of 10µg/mL in complete X-VIVO 15 media.
BDCA-3 DCs were incubated at 37oC for 18 hours to allow for the formation of ILT4
positive cells. Stimulated BDCA-3 DCs were then re-sorted by their expression of ILT4
directly into complete X-VIVO 15 media without further stimulation. 2x104 cells in
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200µL complete X-VIVO 15 media were added to a 96 well plate and incubated for 18
hours at 37oC. Supernatants were harvested and cytokine profiles were assayed with the
ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel (eBiosciences, San
Diego, CA) on a Bioplex 200 System running Bioplex Manager Version 6. Statistics
were performed by running a two-tailed paired student t-test in GraphPad Prism version
6.0. Results with a p value < 0.05 were considered significant. Intracellular FACS
staining of BDCA-3 DCs was performed as follows. Following sorting, total BDCA-3
DCs were added to a FACS tube containing Poly I:C at a final concentration of 10µg/mL
in complete X-VIVO 15 media. BDCA-3 DCs were incubated at 37oC for 18 hours to
allow for the formation of ILT4 positive cells. Golgistop was then added for 6 hours.
Cells were then washed and surface stained with ILT3, ILT4 (R&D Systems,
Minneapolis, MN), CD141 (Miltenyi, San Diego, CA). Following surface staining, cells
were stained with a viability stain that persists through fixation, Live/Dead (Life
Technologies, Waltham, MA) as per the manufacturer’s protocol. Finally, cells were
intracellularly stained with IFN-γ (BioLegend, San Diego, CA), IL-4 (eBiosciences, San
Diego, CA), IL-10 (BD, San Jose, CA), IL-13 (BD, San Jose, CA), IL-5 (BioLegend, San
Diego, CA), and TNF-α (BioLegend, San Diego, CA). Data was collected using a BD
LSRII and analysis was performed with FlowJo Software V9.7 (Treestar, Ashland, OR).
ix.

In vitro priming of naïve CD4+ and CD8+ T cells.

An aliquot of total PBMC was enriched using Human Pan T cell Pre-Enrichment Kit
(StemCell Technologies, Vancouver, BC) for the preparation of allogenic naïve CD4+
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and CD8+ T cells. Total CD4+ and CD8+ T cells were stained and FACS sorted on a BD
FACS ARIA II. Naïve T cells were designated as CD25-, CD127+, CD62L+, and
CD49dlow. BDCA-2 and BDCA-3 DCs were isolated as stated previously. Bulk BDCA2 and BDCA-3 DCs were incubated at 37oC for 18 hours with 3µg/mL CpG2216 or
10µg/mL Poly I:C respectively. After TLR stimulation, BDCA-3 DCs were sorted into
pure populations of ILT4+ and ILT4-. BDCA-2 DCs were washed of CpG2216 prior to
the addition of allogenic T cells. Allogenic naïve CD4+ and CD8+ T cells were incubated
with allogenic BDCA-2 and BDCA-3 DCs (ILT4+ and ILT4-) at a 1:5 DC to T cell ratio
at 37oC in complete X-VIVO 15 media. After 7 days, primed T cells were harvested and
analyzed for cell surface phenotype as well as intracellular staining.
x.

Flow Cytometry.

BDCA-1, BDCA-2, and BDCA-3 DC activation status was assessed using surface
stain markers CD40, CD80, CD86, CCR7, ILT3, and ILT4 from BD Biosciences and
R&D Systems. Cells were stained with fluorescent antibodies for 30 minutes on ice,
washed twice with BD FACS staining buffer (DPBS contains 2% FBS and 0.09% sodium
azide) and then acquired on a BD LSR II. Mean fluorescence intensity and cell
percentages were determined by FlowJo V9.7 (Treestar, Ashland, OR). Cytokine
production by day 7 primed T cells was assessed by intracellular cytokine staining after
initial staining with Cell Trace violet to detect proliferation (Life Technologies, Waltham,
MA). Day 7 primed T cells were stimulated with PMA (50ng/mL; EMD Millipore,
Billerica, MA) and Ionomycin (1µM; Sigma, St. Louis, MO) in the presence of Golgi
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Stop (1 µl/mL; BD Bioscience, San Jose, CA) for 6 hours. After incubation, cells were
first surface stained with antibodies to CD25 (BD, San Jose, CA) and HLAG
(BioLegend, San Diego, CA), 30 minutes on ice. Next, cells were cultured using
Live/Dead stain (Life Technologies, Waltham, MA) according to manufacturer’s
protocol. Finally, cells were stained intracellularly with antibodies against IL-4
(eBiosciences, San Diego, CA), IL-5 (eBiosciences, San Diego, CA), IL-10
(eBiosciences, San Diego, CA), IL-13 (BD, San Jose, CA) and IFN-γ (BD, San Jose,
CA). Data was collected using BD LSRII and analysis was performed with FlowJo
Software V9.7 (Treestar, Ashland, OR).
xi.

EC50 calculations.

All reported EC50 were calculated using the following:
The 4-parameters logistic model has been chosen to fit standard dose-response curves:

a is the lower asymptote; can be constrained by the user (Bottom).
b is the slope at the inflexion point of the curve (Slope) (eg: Hill’s Slope or n-Hill).
c is the difference between upper and lower asymptote (Delta) ; cannot be constrained
directly but via the constraint on upper asymptote (Top) which is “a+c”.
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d is the logarithm of the concentration estimated at inflexion point (CE50 relative); this
parameter cannot be constrained.
Results were obtained using the 4-parameter logistic model according to Ratkovsky and
Reedy (Ratkowsky and Reedy, 1986). The adjustment was obtained by non-linear
regression using the Levenberg-Marquardt algorithm in SAS v9.2 software.
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Results

i.

Blood dendritic cells express a wide range of TLRs

Isolating sufficient numbers of highly enriched pDCs and cDCs for functional assays
requires a large number of input PBMCs. pDCs and cDCs only make up approximately
0.1-0.3% of total PBMCs in healthy individuals, respectively (Rovati et al., 2008). A
two-step enrichment process was devised to facilitate the isolation of sufficient quantities
of both cDCs and pDCs from a leukapheresis pack. First, total blood DCs were enriched
by negative selection, followed by flow cytometry sorting of the enriched DC fractions
for pDCs (Lin-, CD123+, HLADR+), cDCs (Lin-, CD123-, HLADR+, CD1c+, CD11c+),
and BDCA-3 cDCs (Lin-, CD123-, HLADR+, CD1c-, CD141+), (Fig. 1).
Previous studies suggested that primary cDCs and pDCs exhibit distinct patterns of
toll-like receptor (TLR) expression (Kadowaki et al., 2001) as compared to in vitro
moDCs (Chang et al., 2000, Osugi et al., 2002). We therefore wanted to confirm, as
previously reported, the TLR expression profile of highly purified pDC and cDC
populations to ascertain their phenotype prior to TLR agonist profiling. qPCR on the
sorted primary blood DCs revealed that cDCs expressed a wide range of TLRs including
TLR1, TLR2, TLR4, and TLR10. In contrast, pDCs mainly expressed TLRs 7 and 9, and
BDCA-3 cDCs expressed mainly TLR1, TLR3, and TLR10 (Fig. 2). Given that BDCA-3
cDCs expressed a limited repertoire of TLRs, we focused our initial efforts to
characterize the BDCA-3 cDC response to Poly I:C, a TLR3 agonist.
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Figure 1: Blood DC gating strategy for FACS sorting.
Leukapheresis packs were
lysed of red blood cells and then depleted for DC enrichment. pDCs were sorted based on
the expression of cell surface markers Lin-, CD123+, HLADR+. cDCs were sorted based
on cell surface markers as Lin-, CD123dim, HLADR+, CD1c+, and CD11c+. BDCA-3 DCs
were sorted based on cell surface markers as Lin-, CD123dim, HLADR+, CD1c-, and
CD141+. Figure is representative of one donor out of four. (Colletti et al., 2016)

27

Figure 2: Blood DC subsets express different levels of TLRs.
RNA extracted from sorted pDCs, cDCs, and BDCA-3 DCs was reverse transcribed for
qPCR. To determine the relative expression of each gene of interest, genes were
normalized to RPLPO, and the 2−ΔΔCt approach (ΔCq method) was utilized. Data
represent four donors. Error bars represent SEM. (Colletti et al., 2016)
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ii.

Blood DCs are activated by TLR agonists:

Blood DCs were stimulated with various TLR agonists and assessed for activation by
flow cytometry. DC activation with TLR agonists as measured by activation markers
CD40, CD80, and CD86 correlated with the corresponding TLR transcript profile of each
DC. To normalize the magnitude of activation, we calculated fold induction from
baseline. The mean fluorescence intensity (MFI) from stimulated cells was divided by the
MFI of unstimulated cells to yield a fold induction of activation. BDCA-1 DCs were
activated by Poly I:C (TLR3) and Resiquimod (TLR7/8), BDCA-2 DCs were activated
by Resiquimod and CpG2216 (TLR9), and BDCA-3 DCs were activated by Pam3CSK4
(TLR1/2), Poly I:C, and Resiquimod (Fig. 3).
We decided to further evaluate the response of BDCA-3 cDCs following Poly I:C,
stimulation. Stimulation of BDCA-3 cDCs with Poly I:C resulted in activation of these
DCs as indicated by the induction of canonical DC-maturation markers, such as CD40
and CD80/86 as well as inhibitory receptors ILT3 and ILT4 (Fig. 4A) after 18 hours.
CD40, CD80, and CD86 after stimulation with Poly I:C are uniformly upregulated.
Unlike other blood DC subsets (e.g. pDCs), ILT3 and ILT4 up-regulation revealed
several populations of BDCA-3 DCs (Fig. 4B). The appearance of these populations
(ILT3- ILT4-, ILT3- ILT4+, ILT3+ ILT4-, and ILT3+ ILT4+) of BDCA-3 cDCs prompted
us to further investigate their biology.
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Figure 3: Blood DCs activated by TLR agonists up-regulate activation markers.
BDCA-1, BDCA-2, and BDCA-3 DCs were stimulated with TLR 1-10 agonists at
3µg/mL for 18 hours. DC activation status was assessed using surface stain markers
CD40, CD80, CD86, CCR7, ILT3, and ILT4. Values represent a fold of the unstimulated
MFI. Data represents the average of three single donors, error bars represent SEM.
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Figure 4: BDCA-3 DC stimulation with Poly I:C up-regulates inhibitory receptors
ILT3 and ILT4. A) BDCA-3 DCs were stimulated with Poly I:C and LPS at 10μg/mL
for 18 h. Expression of CD80, CD86, CCR7,CD40, ILT3, and ILT4 comparing pre- and
post-stimulation, blue dots represent unstimulated cells and red dots identify cells
stimulated with TLR agonist, with values representing mean fluorescent intensity (MFI).
B) pDCs stimulated with CpG2216 at 3µg/mL and BDCA-3 DCs stimulated with Poly
I:C at 10µg/mL for 18 hours results in a DC subset specific pattern of the up-regulation
of ILT3 and ILT4 (Colletti et al., 2016).
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iii.

Poly I:C activation of BDCA-3 DCs occurs in a dose dependent manner:

The induction of activation markers measured on BDCA-3 DCs after stimulation with
Poly I:C occurred in a dose dependent manner. DCs were considered activated when they
achieved an MFI that was two-fold above the unstimulated value at 18 hours post
stimulation. Two-fold induction for each of the activation markers was calculated: CD40
[3.2µg/mL], CD80 [0.12µg/mL], CD86 [0.17µg/mL], ILT4 [4.3µg/mL], while ILT3 did
not achieve two fold inductions at 18 hours at all doses of Poly I:C tested (Fig. 5).
Measurable cytokine production by BDCA-3 DCs after stimulation with Poly I:C was
detected at higher concentrations than those required to induce activation marker
detection by flow cytometry (Fig. 6).

32

Figure 5: Poly I:C dose response stimulation of BDCA-3 DC activation markers.
BDCA-3 DCs were isolated and then stimulated with varying doses of Poly I:C for 18 hrs
at 37 oC. Cells were the stained with the corresponding activation marker and acquired on
an FACS Fortessa. Fold of the unstimulated values were calculated by dividing the
concentration of interest’s MFI by the unstimulated MFI. EC50 curves and the
concentrations at which 2 fold inductions occurred were calculated as stated in Materials
and Methods section. Data represents the mean of three single donors, error bars
represent SEM.
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Figure 6: Poly I:C dose response on BDCA-3 DC cytokine secretion.
BDCA-3 DCs were isolated and then stimulated with varying doses of Poly I:C for 18hrs
at 37o C. DC cell supernatants were analyzed for cytokine levels using the human
ProcartaPlex Human Cytokine/Chemokine/Growth Factor Panel from eBioscience. EC50
curves were calculated as stated in Materials and Methods section. Data represents three
single donors, error bars show SEM. TNF-α and IL13 EC50’s were not calculated as they
did not fit the curve fitting software.
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iv.

Poly I:C activation of BDCA-3 DCs occurs in a time dependent manner :

BDCA-3 DCs stimulated with Poly I:C at 3µg/mL resulted in minimal up-regulation
of both ILT3 and ILT4 after 18 hours, in order to detect a robust induction of the
activation markers of interest, we used a dose of 10µg/mL for further experimentation.
10µg/mL required several hours of stimulation prior to the detection of activation
markers to occur (Fig. 7). CD40, CD80, and CD86 achieve detectable two-fold activation
at 4.1, 3.2, and 2.5 hours respectively. The detection of ILT4 was further delayed,
achieving a two-fold activation measurement after 5.7 hours. ILT3 induction was also
delayed as compared to the activation marker induction,. ILT3 up-regulation was
detectable only after 8 hours of stimulation. The detection of activation markers occurred
prior to the detection of the inhibitory receptors ILT3 and ILT4 as demonstrated by the
time required to induce a two-fold activation from baseline.
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Figure 7: Poly I:C time course of BDCA-3 DC activation marker up-regulation.
Purified BDCA-3 DCs were added to a FACS tube in complete X-VIVO media. An
aliquot of unstimulated cells was removed and stained as stated in the Flow Cytometry
section prior to the addition of Poly I:C. Poly I:C was then added at a final concentration
of 10µg/mL and cells were incubated at 37oC. An aliquot of cells was removed every
hour, stained, and then acquired. Cells were stained as stated in the Flow Cytometry
Materials and Methods section. Data represents the mean of 3 single donors, error bars
show SEM. ILT3 EC50 and 2 fold activation was not calculated, curves did not fit the
software.
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v.

ILT3 and ILT4 BDCA-3 DC populations exhibit similar activation
marker induction:

To discount the possibility that the various ILT populations (ILT3-ILT4-; ILT3+ILT4-;
ILT3-ILT4+; ILT3+ILT4+) arose due to differential levels and/or threshold of activation,
the maturation status of each of the ILT populations was examined. As shown in Figure
8A, all ILT populations had similar surface expression of DC-maturation associated
markers. To address the specificity of the inductive signal for generating these various
populations of BDCA-3 cDCs, the TLR4 agonist LPS, was added to purified BDCA-3
cDC cultures for 18 hours. As shown in Figure 8B and consistent with the lack of TLR4
transcripts in BDCA-3 cDCs, TLR4 triggering did not promote the up-regulation of ILT3
and ILT4. These data suggests that the inductive signal driving the development of these
populations, designated by the expression of ILT3 and ILT4 on BDCA-3 cDCs is not due
to the in-vitro culturing conditions but rather specific to TLR3-mediated signaling.
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Figure 8: Poly I:C stimulated BDCA-3 DC ILT3 and ILT4 populations are similar
in their expression of activation markers CD40, CD80, and CD86. A) BDCA-3 DCs
were stimulated with 10µg/mL Poly I:C or B) 3µg/mL LPS for 18 hours at 37oC. ILT3
and ILT4 population’s CD40, CD80, and CD86 expression was compared by MFI. Plots
representative of one donor of 4 (Colletti et al., 2016).
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vi.

ILT4+ and ILT4- BDCA-3 DCs have unique cytokine profiles:

Following stimulation of BDCA-3 DCs with Poly I:C, the emergence of several
populations designated by their expression of ILT3 and ILT4 receptors (ILT3- ILT4-,
ILT3+ ILT4-, ILT3+ ILT4+, ILT3- ILT4+), which have suggested inhibitory effects,
prompted us to investigate whether these populations of the TLR3-induced DCs also
exhibit differential cytokine production. Due to limited cell numbers in the ILT3+ILT4+
population, we focused our initial investigative efforts on the cytokine secretion profile of
the ILT4-expressing DCs (Fig. 9). To determine the level of cytokine secretion amongst
the ILT4- vs ILT4+ populations, bulk-sorted BDCA-3 DCs were stimulated with Poly I:C
for the induction of ILT4+/- cells. After 18 hours, ILT4- and ILT4+ populations were
FACs-sorted and re-cultured overnight in the absence of further TLR stimulation. As
demonstrated in Figure 10, multiplex cytokine analysis of the cultured supernatant
revealed quantitative and qualitative differences in the cytokine secretion potential
between the ILT4+ and ILT4- populations. ILT4- cells are unique in their capacity to
produce IFN-ɣ and IP-10, while ILT4+ cells are poised for TNF-α, IL-12p70, and IL-6
production. To confirm the unique cytokine-secreting profiles between ILT4+ and ILT4cells, we performed intracellular cytokine staining (ICS) by stimulating BDCA-3 DCs for
18 hours with Poly I:C and assessed cytokine secretion by each population (Fig. 11).
Consistent with the cytokine analysis, ICS analysis reveal that ILT4- BDCA-3 DCs are
capable of producing IFN-ɣ and low levels of TNF-α, conversely, ILT4+ BDCA-3 DCs
produced exclusively high levels of TNF-α and undetectable levels of IFN-ɣ (Fig. 11).
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Taken together, the data thus far suggested that ILT4- and ILT4+ BDCA-3 DCs are
phenotypically and functionally unique.
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Post

Post

Figure 9: Experimental design of BDCA-3 DC phenotyping.
Purified BDCA-3 DCs were stimulated with 10µg/mL Poly I:C for 18 hours at 37oC. DCs
were then stained with ILT3 and ILT4 and sorted. Purified cells were phenotyped by
various cellular and molecular assays. Data were representative of one donor (Colletti et
al., 2016).
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Figure 10: Multiplex cytokine analysis of ILT4- vs ILT4+ BDCA-3 DCs.
BDCA-3 cDCs were cultured with Poly I:C for 18 h and then sorted into ILT4− and ILT4+
populations. Cells were then plated without further stimulation for 18 hours. Supernatants
were assayed for cytokine and chemokine content by luminex analysis. P-values
generated using two-tailed student’s paired t-test (95% confidence interval). Graphs
represent four single donors. Error bars represented SEM (Colletti et al., 2016).
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Figure 11: Intracellular cytokine analysis of ILT4- vs ILT4+ BDCA-3 DCs.
BDCA-3 cDCs were stimulated with Poly I:C for 18 h, Golgistop was then added for 6
hours. Cells were surface stained with ILT3, ILT4, and CD141 and then intracellularly
stained with IFN-γ and TNF-α. Data showing intracellular staining were representative of
one donor out of four (Colletti et al., 2016).
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vii.

ILT4+ and ILT4- BDCA-3 DCs have unique genomic signatures:

To better understand whether the ILT4+ and ILT4- populations represent DC
populations with unique characteristics, transcriptional profiling was performed on ILT4+
vs ILT4- BDCA-3 DCs after Poly I:C stimulation. General linear models for microarray
data were performed for probe sets present on the microarray to identify probe sets that
are differentially expressed between the groups, based on moderated t-statistics. Probe
sets with a 1.5-fold change and a P value less than 0.05 were considered significant.
Although our analysis revealed unique gene signatures for the ILT4+ vs ILT4populations following stimulation, we were not able to identify unique surface markers to
faithfully distinguish between the two populations. A 3D plot generated by principle
component analysis (PCA) with OmicSoft ArrayStudio across all probe sets revealed that
ILT4+ cells are most dissimilar from ILT4- cells (Fig. 12A). The ILT4- population
revealed up-regulated genes involved in T cell stimulation, in particular IFN-ɣ, which
was consistent with multiplex cytokine and ICS analysis (Fig. 10-11). Finally, the ILT4+
population revealed the up-regulation of two inhibitory receptors, ILT4 and ILT6. The
ILT4 expression of the ILT4+ population was confirmed by real-time PCR analysis (Fig.
12B). The microarray analysis of the ILT4+ population showed up-regulation of the TNFα gene, these results were all consistent with both multiplex cytokine analysis and FACS
intracellular staining (Fig. 10-11). Collectively, the functional and genomic analysis of
ILT4+ and ILT4- cells suggested that these cells are distinct DC populations found within
the broader BDCA-3 DC subset.
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Figure 12: Microarray analysis of ILT4+ vs ILT4- BDCA-3 DCs.
Genomic profiling of ILT4− vs. ILT4+ was performed using GeneChip Human Gene 1.0
ST arrays. Principal component analysis (PCA) was computed using OmicSoft
ArrayStudio, and a plot was generated to show the relative clustering of ILT4− and
ILT4+. ILT4− and ILT4+ populations were compared to each other by t-test with a
threshold set for a fold change >1.5 and a P-value <0.05. ILT4 gene expression was
confirmed by qPCR. (Data shown are one representative donor out of four, error bars
represented SEM) (Colletti et al., 2016).
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viii.

BDCA-3 DCs prime naïve CD4 T cells towards a Th1 phenotype:

To characterize the ability for BDCA-3 DCs to prime naïve T cells, we compared
their priming potential with pDCs (BDCA-2 DCs). To this end, BDCA-2 and BDCA-3
DCs were stimulated with CpG2216, a TLR9 agonist, and Poly I:C, respectively.
Following stimulation, both activated DC subsets were co-cultured with allogenic sorted
naïve CD4+ T cells at a DC to T cell ratio of 1 to 5. On day 7 post priming, the phenotype
of the resultant CD4+ T cells was assessed by flow-cytometry for the secretion of
prototypic Th1- and Th2-associated cytokines. Interestingly, both DC subsets primed
naïve CD4 T cells towards different Th phenotypes. pDCs stimulated with a TLR9
agonist resulted in the priming of T cells towards a Th2 phenotype, mainly secreting IL-4
(6%) and IL-10 (33%). BDCA-3 DCs stimulated with Poly I:C resulted in the priming of
T cells towards a Th1 phenotype, secreting mostly IFN-ɣ (75%) (Fig. 13). To further
investigate the ability for BDCA-3 DCs to prime naïve T cells, we decided to compare
the priming capabilities of ILT4- vs ILT4+ BDCA-3-DCs following Poly I:C stimulation.
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Figure 13: BDCA-2 and BDCA-3 DC priming of naïve CD4 T cell outcomes.
Bulk BDCA-2 and BDCA-3 DCs were incubated at 37oC for 18 hours with 3µg/mL
CpG2216 or 10µg/mL Poly I:C respectively. After TLR stimulation, BDCA-3 DCs were
sorted into pure populations of ILT4+ and ILT4-. BDCA-2 DCs were washed of CpG2216
prior to the addition of allogenic T cells. Allogenic naïve CD4+ and CD8+ T cells were
incubated with allogenic BDCA-2 and BDCA-3 DCs (ILT4+ and ILT4-) at a 1:5 DC to T
cell ratio at 37oC in complete X-VIVO 15 media. After 7 days, primed T cells were
harvested and analyzed for intracellular cytokine staining. Data represented one donor out
of three.
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ix.

ILT4- and ILT4+ BDCA-3 DCs differ in their ability to prime allogenic
naïve T cells:

The differences in cytokine secretion and transcriptional profiles of ILT4- and ILT4+
BDCA-3 DCs implied that these DC populations may have distinct T cell priming
potential. To address this possibility we assessed the ability of each ILT4 population to
prime naïve CD4+ and CD8+ T cells. To this end, BDCA-3 DCs were first stimulated
with Poly I:C and subsequently sorted to high purity into ILT4- and ILT4+ populations.
The sorted ILT4 populations were then co-cultured with allogenic sorted naïve CD4+ and
CD8+ T cells at a DC to T cell ratio of 1 to 5. T cells were then stained with Cell Trace
prior to the mixed lymphocyte reaction (MLR) to assess the level of their proliferation.
Proliferation with Cell Trace is detected by a dilution of the incorporated dye within the
cell membrane following subsequent cellular divisions. On day 7 post priming, the
phenotype of the resultant CD4+ and CD8+ T cells was assessed by flow-cytometry for
the secretion of prototypic Th1- and Th2-associated cytokines, such as IFN-ɣ and IL-4,
respectively. Both ILT4+ and ILT4- DCs demonstrated the capacity to prime both naïve
CD4+ and CD8+ T cells as demonstrated by the dilution of Cell Trace dye (Figs. 14-15).
More importantly, both DC populations preferentially primed naïve CD4+ and CD8+ T
cells towards IFN-ɣ Th1 cells (Fig. 14-15). IL-4 producing cells were also observed, but
at a much lower frequency than IFN-ɣ producing cells. Despite the ability to prime naïve
CD4+ and CD8+ T cells towards a Th1 phenotype, ILT4+ DCs appeared to be less
efficient at promoting Th1 induction as compared to ILT4- DCs (Figs. 14-15). CD4+ T
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cell activation remained largely intact, while the priming of CD8+ T cells was impaired
by as much as 53% when co-cultured with ILT4+ DCs (Figs. 14-15).
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Figure 14: ILT4- and ILT4+ BDCA-3 DC mixed lymphocyte reactions (MLRs).
BDCA-3 cDCs were cultured with Poly I:C for 18 h. Cells were then sorted into ILT4−
and ILT4+ populations and incubated with naïve CD4 allogenic T cells (CD25−, CD127+,
CD62L+, CD49dlow). After 7 days, the resultant T cells were assessed for surface marker
and intracellular cytokine expression. Dot plots are gated on live CD3+ and CD4+ T cells.
Data shown were one representative donor out of four (Colletti et al., 2016).
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Figure 15: ILT4- and ILT4+ BDCA-3 DC mixed lymphocyte reactions (MLRs).
BDCA-3 cDCs were cultured with Poly I:C for 18 h. Cells were then sorted into ILT4−
and ILT4+ populations and incubated with naïve CD8 allogenic T cells (CD25−, CD127+,
CD62L+, CD49dlow). After 7 days, the resultant T cells were assessed for surface marker
and intracellular cytokine expression. Dot plots are gated on live CD3+ and CD8+ T cells.
Data shown were one representative donor out of four (Colletti et al., 2016).
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x.

ILT4+ BDCA-3 DCs impaired T cell priming is IL-10 independent:

To examine the ILT4+ DC impaired T cell priming, we examined the expression of
HLA-G, a known ligand for the ILT4 receptor (Ristich et al., 2005). Cell surface
expression of HLA-G has been implicated in the induction of tolerogenic functions in
various physiological and pathological settings (Jurisicova et al., 1996, Rouas-Freiss et
al., 1997, Paul et al., 1998, Braud et al., 1999). Assessment of the T cell expression of
HLA-G after priming with ILT4+ and ILT4- DCs revealed that CD8+ T cells primed in the
presence of ILT4+ DCs showed an approximately 9 fold increase in HLA-G expression as
compared to CD8+ T cells co-cultured with ILT4- DCs (Fig. 16A). On the other hand,
there was no observable induction of HLA-G expression on CD4+ T cells co-cultured
with either ILT4+ or ILT4- DCs. The observed impaired T cell priming ability of ILT4+
DCs could be the result of active inhibition by suppressor CD8+ T cells expressing HLAG. To this end, we investigated the level of IL-10, a known anti-inflammatory cytokine
secreted by various cell types, including T regulatory cells (O'Garra et al., 2004), in our
DC primed T cell cultures. As shown in Figure 16B, we found similar levels of T cellderived IL-10 in both ILT4-positive and –negative DCs primed T cell cultures. Taken
together this data suggests a potential IL-10-independent mechanism of dampening DC
priming capabilities.
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Figure 16: ILT4- and ILT4+ BDCA-3 DC MLR CD8 T cell HLAG expression and
IL-10 supernatant levels.
A) MLR CD8 T cells were stained with HLAG after 7 days of ILT4- or ILT4+ BDCA-3
DC priming. B) CD4 and CD8 T cell MLR supernatants were harvested after 7 days and
assessed for the level of IL-10. Error bars show SEM. (Colletti et al., 2016)
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Discussion:
Prior to profiling human blood DC stimulation with TLR agonists, we
characterized their TLR expression pattern. Genomic transcript analysis of human blood
DC TLR expression revealed that different DC subsets expressed different levels of TLRs
(Fig. 2). BDCA-1 DCs expressed a wide range of TLRs while BDCA-2 expression was
restricted to mainly TLR 7 and 9. BDCA-3 DCs mainly expressed TLR3 which is
consistent with previous studies (Hornung et al., 2002). We also observed that BDCA-3
DCs expressed high levels of TLR10, which suggests functional TLR10 protein. The role
that TLR10 plays in the immune response as well as the ligand remains to be elucidated.
Transcript expression of various TLR receptors and responsiveness to multiple TLR
agonists suggests two hypotheses (A) on per cell basis BDCA-3 DCs express multiple
TLRs or (B) there may exist various BDCA-3 DC subsets each with a unique TLR
expression. The recent discovery of a human XCR1+CD141+ DC subset expressing TLR3
within the conventional DC population supports the latter hypothesis (Bachem et al.,
2010). This discovery raises the possibility that multiple yet-to-be-identified populations
of BDCA-3 DCs may exist.
Currently, human blood DCs can be identified and purified based on various
surface expression markers. BDCA-1 DCs can be isolated by the absence of lineage
marker expression (Lin-), HLADR+, CD1c+, and CD11c+. BDCA-2 DCs identified by
Lin-, HLADR+, and CD123+. BDCA-3 DCs identified by Lin-, HLADR+, CD1c-, and
CD141+. In the present study, we demonstrated that stimulation of BDCA-1, 2, and 3
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with various TLR agonists induced the expression of canonical markers associated with
DC activation/maturation, such as CD40, CD80, and CD86 (Fig. 3). This activation with
TLR agonists correlated with the TLR transcript profile of each DC subset, for example,
BDCA-2 DCs showed high levels of TLR 7 and 9 gene expression and upon stimulation
with CpG2216 (TLR9 agonist) showed a 10 fold increase in CD40 and a 3 fold increase
in CD86 (Figs. 2-3). Poly I:C stimulation of BDCA-3 DCs induced the expression of
CD40, CD80, CD86, ILT3, and ILT4 as detected by flow cytometry (Fig. 4A). The
induction of BDCA-3 activation markers occurred in a dose dependent manner and was
specific for each activation marker. CD80 achieved a 2 fold increase in MFI at
concentrations as low as 0.12ug/mL of Poly I:C, while CD40 required approximately
3.18 µg/ml Poly I:C (Fig. 5). Multiplex cytokine analysis revealed that BDCA-3 DCs
secrete cytokines at higher concentrations of Poly I:C than is required for the upregulation of activation markers (Fig. 5-6). Measurable levels of IFN-ɣ and TNF-α were
detectable after stimulation of BDCA-3 DCs with 0.1µg/mL Poly I:C (Fig. 6) whereas
CD86 up-regulation occurs after stimulation with 0.01µg/mL Poly I:C (Fig. 5).
Unlike the activation markers CD40, CD80, and CD86, the expression pattern of
the ILT receptors allowed for the distinction of various populations, namely ILT3- ILT4-,
ILT3+ ILT4-, ILT3- ILT4+, and ILT3+ ILT4+, within the total BDCA-3 DC population.
The various ILT populations observed after Poly I:C stimulation of BDCA-3 DCs is
unique to this particular blood DC subset. Stimulation of BDCA-2 DCs with CpG2216, a
TLR9 agonist, resulted in the uniform up-regulation of ILT3 and ILT4 (Fig. 4B). ILT3
and ILT4 are surface proteins of the immunoglobulin superfamily, which have been
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demonstrated to be expressed on monocytes and DCs. The cytoplasmic region of ILT
molecules contains a putative immunoreceptor tyrosine-based inhibitory motif,
suggesting an inhibitory function of ILT receptors. Consistent with the proposed
inhibitory function, ILT3 has been shown to induce immunosuppression, including T cell
anergy, regulatory T cell (Treg) induction, and reduced allo-stimulatory capacity (Chang
et al., 2002, Manavalan et al., 2003). We further investigated the expression of activation
markers within each ILT sub-population as well as the time required for receptor upregulation. CD40, CD80, and CD86 are rapidly up-regulated and detectable after just 2
hours of stimulation with 10µg/mL Poly I:C. The inhibitory receptor ILT4 was further
delayed in its up-regulation and was measurable by flow cytometry after 5 hours of
stimulation with 10µg/mL Poly I:C (Fig. 7), ILT3 detectable only after 8 hours of
stimulation. This delay in inhibitory receptor expression may contribute to an immune
dampening process after a rapidly occurring immune response. Each described ILT
population shows similar expression of CD40, CD80, and CD86, this lead us to
hypothesize the potential for functional differences among these various ILT expressing
DC populations (Fig. 8).
Previous studies have generated BDCA-3 DCs from monocytes in the presence of
various growth factors and cytokines. In the presence of IL-10, these DCs, termed DCIL10, expressed high levels of ILT receptors, namely ILT2 and ILT3 (Velten et al.,
2004). These in vitro derived DCs retained immunosuppressive functions, including
IL10 production and the ability to generate CD4+ Tregs (Velten et al., 2004). BDCA-3
DCs have also been found outside of the blood. ILT3+ expressing BDCA-3 DCs have
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been identified in the dermis of the human skin. These dermal DCs were shown to
produce IL-10, induce T cell hyporesponsiveness, and were able to inhibit skin
inflammation by inducing Tregs (Chu et al., 2012). In addition to ILT3 expression on
BDCA-3 DCs, ILT4 was detected by gene array analysis following Poly I:C stimulation
(Balan et al., 2014). The various ILT populations we detected after Poly I:C stimulation
on primary BDCA-3 DCs occur in varying cell frequencies. ILT4-ILT3+ and ILT4+ILT3+
cell numbers post Poly I:C stimulation cell were consistently limited so we focused our
studies on profiling ILT4+/- ILT3- BDCA-3 DCs. We first sorted ILT4- and ILT4+
BDCA-3 DCs after Poly I:C stimulation and compared their transcriptional profiles by
microarray. Complementing the detection of ILT4 by flow cytometry, the expression of
ILT4 transcript was increased in the ILT4+ BDCA-3 DC microarray samples. To further
validate this ILT4 expression, we performed Taqman analysis on ILT4+ BDCA-3 DCs
after sorting. ILT4+ DCs expression of ILT4 was 5 fold higher than the ILT4- isolated
DCs (Fig. 12B). ILT6 expression was also highest in the ILT4+ expressing DCs (Fig.
12A). ILT6, unlike other ILT members, lacks a transmembrane domain and is a soluble
receptor (Torkar et al., 2000). As immune modulators, the heightened expression of ILT4
and ILT6 may work in synergy to modulate T cell priming in ILT4+ DC MLR reactions
(Fig. 14-15). ILT6 has been implicated as both an immune-stimulatory or antiinflammatory protein with a reduced affinity for HLA-G as compared to ILT4 (An et al.,
2010, Ryu et al., 2011, Low et al., 2013). ILT6 may compete with ILT4 to maintain an
ongoing immune response in the presence of HLA-G. The ILT4+ BDCA-3 DCs also
expressed higher levels of transcripts for interleukin-12 beta-subunit (IL-12b/IL-12p40)
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and tumor necrosis factor α (TNF-α) (Fig. 12A). IL-12b, a shared subunit for both
bioactive IL-12p70 and IL-23, may promote the generation of either T-helper 1 (Th1)
and/or Th17 cells. IL-12p70 was also greater in expression within the ILT4+ BDCA-3
DCs. TNF-α is a well-studied pro-inflammatory cytokine. TNF-α is known for its ability
to induce systemic inflammation and the acute phase reaction. TNF-α regulates the
expansion and survival of CD4+ and CD8+ T cells and has been implicated in the
progression of various diseases (Beutler et al., 1985, Locksley et al., 2001, Gaur and
Aggarwal, 2003). A migratory chemokine, CCL3, was also produced exclusively by the
ILT4+ BDCA-3 DCs (Fig. 16A). CCL3 has been shown to enhance the differentiation,
migration, and effector functions of CD8+ T cells (Trifilo et al., 2003). Based upon the
ILT4+ BDCA-3 DC cytokine profile detected by microarray analysis, they may function
to provide a link between innate and adaptive immunity. On the contrary, the ILT4BDCA-3 DCs showed mostly type II interferon (IFN-ɣ) (Fig. 12A). The microarray
genomic expression of IFN-ɣ was further confirmed at the protein level by both
intracellular FCS and multiplex cytokine analysis (Fig. 10-11). IFN-ɣ plays several roles
in both the innate and adaptive immune response. Studies show that it is involved in antiviral, -bacterial, and -tumor biology (Ikeda et al., 2002, Perry et al., 2005, Hermant and
Michiels, 2014). IP-10 levels were also elevated in the supernatant of cultured ILT4BDCA-3 DCs. IP-10 secretion is intricately linked to the output levels of IFN-ɣ
production. As a migratory chemokine, IP-10 is known to induce chemotaxis of
numerous leukocytes (Taub et al., 1993, Jinquan et al., 2000). Along with cytokines, the
ILT4- BDCA-3 DCs also express various surface marker immune activators including

58

CD48, CD84, and CD74 (Fig. 12A). CD84 is expressed mainly on monocytes,
macrophages, granulocytes, and DCs and is involved in leukocyte activation (Sintes et
al., 2010). CD74 regulates the class II major histocompatibility complex (MHC) proteins
in APCs. The induction of such activation markers may partially contribute to their
ability to more efficiently prime naïve CD4+ T cells (Fig. 14) (Beswick and Reyes, 2009).
The discovery of various populations of BDCA3+ DCs after stimulation with a TLR3
agonist lead us to hypothesize that these populations could be delineated by a newly
discovered subset expressing XCR1 (Bachem et al., 2010). XCR1+ BDCA3+ DCs have
been shown to have a high capacity for cross-presentation and have the ability to both
acquire and present necrotic antigens (Bachem et al., 2010, Balan et al., 2014). Our
microarray analysis did not reveal any differences in the expression of XCR1 within the
ILT4- and ILT4+ populations, suggesting that their expression is independent of the
expression of XCR1. Through genomic profiling of these two different ILT expressing
DCs, we have shown that they express different immunological surface markers as well
as have unique cytokine transcript profiles.
DCs have the ability to prime naïve T cells towards various T-helper cell
phenotypes. The outcome of T cell priming is influenced by many factors. The DC
subset as well as the maturation status of the DC during the priming event can lead to
different T helper outcomes (Langenkamp et al., 2000, Kushwah and Hu, 2011). We have
shown that BDCA-2 DCs stimulated with a TLR9 agonist results in the priming of naïve
CD4 T cells towards a Th2 phenotype, while BDCA-3 DCs simulated with a TLR3
agonist primes naive CD4 T cells towards a Th1 profile (Fig. 13). DCs of the same
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lineage may also differ in their priming capacity based upon their physical location.
Studies have shown that skin BDCA-3 DCs secrete high levels of IL-10 and induce T
regulatory cells (Chu et al., 2012). High ILT3 expression on BDCA-3 DCs has been
previously shown to be involved in the impairment of allo-stimulatory priming of naïve T
cells (Velten et al., 2004). We have shown in our study that BDCA-3 DCs expressing
high levels of ILT4 also have a reduced allo-stimulatory capacity that is more prominent
for CD8+ T cells (Fig. 15). The difference in the capacity of the ILT expressing BDCA-3
DCs to prime T cells might be linked to the activity of the ILT4 receptor. A natural ligand
of the ILT4 receptor is a non-classical class I heavy chain MHC molecule, HLA-G
(Colonna et al., 1998). HLA-G has been previously shown to inhibit in vitro allogenic
MLRs and can be expressed on T cells (Riteau et al., 1999, Le Friec et al., 2003). We
tested for the expression of HLA-G on primed T cells after the MLR with BDCA-3 DCs.
ILT4+ DCs that primed CD8+ T cells skewed their polarization towards a Th1 phenotype
and induced the expression of HLA-G (Fig. 20). HLA-G has been associated with the
induction of IL-10 producing T suppressor cells (Carosella et al., 2011, Raker et al.,
2015). We tested the levels of IL-10 in the resulting supernatants of our allogenic MLRs
and did not detect any differences between the cultures containing ILT4- or ILT4+ DCs
(Fig. 16B), suggesting an IL-10 independent means of attenuation. These results are
consistent with a previous study indicating that HLAG+ T cells present within whole
PBMCs do not mediate suppression through IL-10 secretion (Feger et al., 2007). The
induction of HLA-G on primed T cells with a distinct DC population may suggest an
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immuno-suppressive mechanism that could potentially prevent the overstimulation of the
adaptive branch of the response.
In the present study, we have shown that a purified population of BDCA-3 DCs
upon stimulation with Poly I:C, rapidly up-regulates canonical activation markers CD40,
CD80, and CD86 which leads to the secretion of various cytokines. This up-regulation of
activation markers occurs in both a dose and time dependent manner. Stimulating
purified BDCA-3 DCs with 10µg/mL Poly I:C for 18 hours resulted in the expression of
inhibitory receptors ILT3 and ILT4. The increased expression of ILT3 and ILT4 was not
uniform as was detected with various activation markers and does not correlate to the
recently discovered expression of XCR1. ILT4 expressing BDCA-3 DCs have a unique
cytokine secreting and genomic profile as compared to ILT4 negative BDCA-3 DCs.
Allogenic CD8 T cell priming is attenuated upon co-culture with ILT4+ BDCA-3 DCs as
compared to ILT4- BDCA-3 DCs. CD8 T cells primed by ILT4+ BDCA-3 DCs showed
expression of HLA-G which could account for the impaired priming during the MLR.
Taken together, these populations of BDCA-3 DCs may work to mediate various aspects
of an immunological response.
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